Clinical Trial Update: Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sequential GSK3228836 and peginterferon in chronic hepatitis B has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GSK3228836
• Peginterferon (Pegylated interferon)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2024-05-02